ArticleInternational journal of molecular sciences2024
Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer.
Emma Franco-Mateos et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.